Caladrius Biosciences Company Profile (NASDAQ:CLBS)

About Caladrius Biosciences

Caladrius Biosciences logoCaladrius Biosciences, Inc., formerly NeoStem, Inc., through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell-based gene therapy). PCT specializes in cell and cell-based gene therapies. PCT offers development and manufacturing capabilities, quality systems, cell and tissue processing, logistics, storage and distribution and engineering solutions to clients with therapeutic candidates at all stages of development. The Company's product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient's own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company's T Regulatory Cell Technology is applicable to multiple autoimmune and allergic diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CLBS
  • CUSIP:
Key Metrics:
  • Previous Close: $5.23
  • 50 Day Moving Average: $4.16
  • 200 Day Moving Average: $4.37
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.29
  • P/E Growth: -0.02
  • Market Cap: $42.72B
  • Beta: 1.01
Profitability:
  • Net Margins: -183.36%
  • Return on Equity: -270.38%
  • Return on Assets: -60.07%
Debt:
  • Debt-to-Equity Ratio: 0.36%
  • Current Ratio: 1.62%
  • Quick Ratio: 1.62%
Additional Links:
Companies Related to Caladrius Biosciences:

Analyst Ratings

Consensus Ratings for Caladrius Biosciences (NASDAQ:CLBS) (?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $3.88 (25.91% downside)

Analysts' Ratings History for Caladrius Biosciences (NASDAQ:CLBS)
Show:
DateFirmActionRatingPrice TargetDetails
11/9/2016Chardan CapitalReiterated RatingBuy$6.50View Rating Details
9/7/2016HC WainwrightReiterated RatingBuyView Rating Details
5/14/2016Maxim GroupReiterated RatingHoldView Rating Details
4/30/2016Rodman & RenshawUpgradeBuyView Rating Details
1/26/2016AegisReiterated RatingBuyView Rating Details
9/24/2015WBB SecuritiesReiterated RatingBuy$7.00View Rating Details
8/7/2015Benchmark Co.DowngradeBuy -> Hold$12.00 -> $2.00View Rating Details
4/6/2015MLV & Co.Initiated CoverageBuy$14.00View Rating Details
(Data available from 2/20/2015 forward)

Earnings

Earnings History for Caladrius Biosciences (NASDAQ:CLBS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2017        
11/7/2016Q3($1.55)($1.09)ViewListenView Earnings Details
8/9/2016Q216($1.75)($1.33)$7.53 million$8.30 millionViewN/AView Earnings Details
3/15/2016Q4($0.28)($0.59)$7.67 million$7.60 millionViewListenView Earnings Details
8/6/2015Q215($0.31)($0.31)$4.70 millionViewN/AView Earnings Details
3/2/2015($0.42)($0.32)ViewN/AView Earnings Details
11/3/2014($0.41)($0.44)ViewN/AView Earnings Details
8/11/2014($0.28)($0.38)ViewN/AView Earnings Details
5/8/2014($0.40)($0.49)ViewN/AView Earnings Details
11/14/2012Q312($0.05)($0.06)$3.50 million$4.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Caladrius Biosciences (NASDAQ:CLBS)
Current Year EPS Consensus Estimate: $-5.06 EPS
Next Year EPS Consensus Estimate: $-2.28 EPS

Dividends

Dividend History for Caladrius Biosciences (NASDAQ:CLBS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Caladrius Biosciences (NASDAQ:CLBS)
Insider Ownership Percentage: 13.10%
Institutional Ownership Percentage: 19.42%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/7/2017Eric WeiDirectorSell6,575$4.77$31,362.75View SEC Filing  
2/6/2017Eric WeiDirectorSell8,425$4.61$38,839.25View SEC Filing  
7/1/2016Eric WeiDirectorSell87,500$0.60$52,500.00View SEC Filing  
6/24/2016Eric WeiDirectorSell22,698$0.55$12,483.90View SEC Filing  
8/17/2015David J MazzoCEOBuy20,000$1.40$28,000.00View SEC Filing  
8/11/2015Robert S VatersCFOBuy81,000$1.24$100,440.00View SEC Filing  
12/9/2014Steven S MyersDirectorBuy20,000$3.56$71,200.00View SEC Filing  
12/8/2014Rimasia Capital Partners ManagDirectorSell16,060$3.75$60,225.00View SEC Filing  
12/3/2014Rimasia Capital Partners ManagDirectorSell12,000$4.01$48,120.00View SEC Filing  
12/1/2014Steven S MyersDirectorBuy10,000$3.92$39,200.00View SEC Filing  
11/25/2014Steven M KloskDirectorBuy10,000$3.99$39,900.00View SEC Filing  
11/24/2014Andrew L PecoraInsiderBuy12,500$4.01$50,125.00View SEC Filing  
11/24/2014Steven S MyersDirectorBuy19,800$3.94$78,012.00View SEC Filing  
12/12/2013Richard BermanDirectorSell12,218$5.99$73,185.82View SEC Filing  
12/9/2013Rimasia Capital Partners Managmajor shareholderSell12,530$6.37$79,816.10View SEC Filing  
12/28/2012Richard J BermanDirectorSell149,306$0.59$88,090.54View SEC Filing  
9/18/2012Richard J BermanDirectorSell36,000$0.69$24,840.00View SEC Filing  
9/17/2012Rimasia Capital Partners ManagMajor ShareholderSell30,000$0.71$21,300.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Caladrius Biosciences (NASDAQ:CLBS)
DateHeadline
News IconStock Perspective: Caladrius Biosciences Inc (NASDAQ:CLBS) Earnings in View - Aiken Advocate (NASDAQ:CLBS)
aikenadvocate.com - February 16 at 10:49 AM
News IconReviewing Indicator Levels for Caladrius Biosciences Inc. (CLBS) - Sherwood Daily (NASDAQ:CLBS)
sherwooddaily.com - February 4 at 9:25 PM
News IconTechnical Trading: Focus on Shares of Caladrius Biosciences Inc. (CLBS) - Sherwood Daily (NASDAQ:CLBS)
sherwooddaily.com - February 3 at 2:48 AM
News IconInside Track: Trading Focus on Shares of Caladrius Biosciences Inc. (CLBS) - Sherwood Daily (NASDAQ:CLBS)
sherwooddaily.com - February 2 at 2:40 AM
globenewswire.com logoCaladrius Biosciences to Present at Upcoming February Conferences - GlobeNewswire (press release) (NASDAQ:CLBS)
globenewswire.com - February 2 at 2:40 AM
finance.yahoo.com logoCaladrius Biosciences to Present at Upcoming February Conferences (NASDAQ:CLBS)
finance.yahoo.com - February 1 at 4:36 PM
News IconTrading Lines in Focus for Caladrius Biosciences Inc. (CLBS) - Sherwood Daily (NASDAQ:CLBS)
sherwooddaily.com - January 31 at 4:45 PM
News IconInvestor Focus on Technical Levels for Caladrius Biosciences Inc. (CLBS) - Sherwood Daily (NASDAQ:CLBS)
sherwooddaily.com - January 30 at 5:14 PM
News IconTrading Views: Checking the Numbers for Caladrius Biosciences Inc. (CLBS) - Sherwood Daily (NASDAQ:CLBS)
sherwooddaily.com - January 25 at 5:25 PM
News IconEarnings in Full Force, Analysts Take Aim at Caladrius Biosciences Inc (NASDAQ:CLBS) - Wall Street Beacon (NASDAQ:CLBS)
wsbeacon.com - January 25 at 5:25 PM
finance.yahoo.com logoCaladrius Biosciences Announces Addition of Three Clinical Sites, Including University of California, San Francisco, for the Ongoing Phase 2 Study of CLBS03 in T1D (NASDAQ:CLBS)
finance.yahoo.com - January 25 at 5:25 PM
News IconEquity Insight: Indicator Review for Caladrius Biosciences Inc. (CLBS) - Sherwood Daily (NASDAQ:CLBS)
sherwooddaily.com - January 18 at 4:39 PM
News IconEarnings Analysis & Update for Caladrius Biosciences Inc (NASDAQ:CLBS)? - Aiken Advocate (NASDAQ:CLBS)
aikenadvocate.com - January 18 at 4:39 PM
News IconShooting From the Hip, Stock Reaches Most Volatile List: Caladrius Biosciences, Inc. (NASDAQ:CLBS) - Wall Street Beacon (NASDAQ:CLBS)
wsbeacon.com - January 18 at 4:39 PM
marketexclusive.com logoCALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS) Files An 8-K Other Events - Market Exclusive (NASDAQ:CLBS)
marketexclusive.com - January 9 at 5:28 PM
us.rd.yahoo.com logo4:02 pm Caladrius Biosciences has not received $6 mln from investor in previously announced private placement -- targeted to be received in Q4 (NASDAQ:CLBS)
us.rd.yahoo.com - January 6 at 9:45 PM
biz.yahoo.com logoCALADRIUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:CLBS)
biz.yahoo.com - January 6 at 9:45 PM
publicnow.com logoCaladrius Biosciences Updates Status of Receipt of Funds for a Portion of Previously Announced Private Placement (NASDAQ:CLBS)
www.publicnow.com - January 6 at 4:45 PM
News IconCaladrius Biosciences Inc CLBS Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:CLBS)
www.bioportfolio.com - January 5 at 4:52 PM
News IconUnder the Microscope We Place Shares of Caladrius Biosciences, Inc. (NASDAQ:CLBS) - Prospect Journal (NASDAQ:CLBS)
prospectjournal.com - January 3 at 11:09 PM
News IconAnalysts Projecting Upside, Can This Stock Surge Higher: Caladrius Biosciences, Inc. (NASDAQ:CLBS) - Prospect Journal (NASDAQ:CLBS)
prospectjournal.com - January 3 at 12:53 PM
globenewswire.com logoCaladrius Biosciences to Present at Upcoming January Conferences - GlobeNewswire (press release) (NASDAQ:CLBS)
globenewswire.com - January 3 at 12:53 PM
finance.yahoo.com logoCaladrius Biosciences to Present at Upcoming January Conferences (NASDAQ:CLBS)
finance.yahoo.com - January 3 at 12:53 PM
marketexclusive.com logoCALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS) Files An 8-K Departure of Directors or Certain Officers; Election of ... - Market Exclusive (NASDAQ:CLBS)
marketexclusive.com - December 31 at 4:24 PM
4-traders.com logoUtilities Down Sightly Amid Trend Reversals - Utilities Roundup (NASDAQ:CLBS)
www.4-traders.com - December 30 at 9:47 PM
capitalcube.com logoETFs with exposure to Caladrius Biosciences, Inc. : December 27, 2016 (NASDAQ:CLBS)
www.capitalcube.com - December 27 at 4:36 PM
News IconTechnical Indicator Review on Shares of Caladrius Biosciences Inc. (CLBS) - Yankee Analysts (NASDAQ:CLBS)
yankeeanalysts.com - December 22 at 3:06 AM
News IconGrowth Story Unfolding for Caladrius Biosciences, Inc. (NASDAQ:CLBS) - Prospect Journal (NASDAQ:CLBS)
prospectjournal.com - December 20 at 8:20 AM
News IconCompany Watch: Focusing on Shares of Caladrius Biosciences, Inc. (NASDAQ:CLBS) - Liberty News (NASDAQ:CLBS)
libertynewsrecord.com - December 20 at 8:20 AM
News IconWatching the Technicals on Shares of Caladrius Biosciences Inc. (CLBS) - Yankee Analysts (NASDAQ:CLBS)
yankeeanalysts.com - December 20 at 8:20 AM
News IconStock Concentration on Shares of Caladrius Biosciences, Inc. (NASDAQ:CLBS) - Highland Digest (NASDAQ:CLBS)
highlanddigest.com - December 18 at 4:22 PM
capitalcube.com logoETFs with exposure to Caladrius Biosciences, Inc. : December 16, 2016 (NASDAQ:CLBS)
www.capitalcube.com - December 16 at 4:44 PM
News IconNumbers in View on Shares of Caladrius Biosciences, Inc. (NASDAQ:CLBS) - Business Daily Leader (NASDAQ:CLBS)
businessdailyleader.com - December 15 at 4:46 PM
News IconChecking on CCI, MA, RSI and ADX for Caladrius Biosciences Inc. (CLBS) - Yankee Analysts (NASDAQ:CLBS)
yankeeanalysts.com - December 15 at 4:46 PM
News IconEnterprise Value Check for Caladrius Biosciences, Inc. (NASDAQ:CLBS) - OIB News (NASDAQ:CLBS)
oibnews.com - December 13 at 6:47 AM
News IconChecking on Shares of Caladrius Biosciences, Inc. (NASDAQ:CLBS) - Liberty News (NASDAQ:CLBS)
libertynewsrecord.com - December 9 at 4:39 PM
News IconTrading Lines in Focus for Caladrius Biosciences Inc. (CLBS) - Yankee Analysts (NASDAQ:CLBS)
yankeeanalysts.com - December 8 at 10:10 PM
News IconComposite Score Check on Caladrius Biosciences, Inc. (NASDAQ:CLBS) - OIB News (NASDAQ:CLBS)
oibnews.com - December 7 at 9:59 PM
globenewswire.com logoCaladrius Biosciences to Present at Upcoming December Conferences - GlobeNewswire (press release) (NASDAQ:CLBS)
globenewswire.com - December 7 at 7:13 AM
News IconNarrowing in on the Numbers for Caladrius Biosciences, Inc. (NASDAQ:CLBS) - Liberty News (NASDAQ:CLBS)
libertynewsrecord.com - December 7 at 7:13 AM
News IconInvestor Corner: Checking the Charts for Caladrius Biosciences Inc. (CLBS) - Yankee Analysts (NASDAQ:CLBS)
yankeeanalysts.com - December 7 at 7:13 AM
finance.yahoo.com logoCaladrius Biosciences to Present at Upcoming December Conferences (NASDAQ:CLBS)
finance.yahoo.com - December 5 at 12:30 PM
News IconStock Tracker: Focusing on Shares of Caladrius Biosciences, Inc. (NASDAQ:CLBS) - Liberty News (NASDAQ:CLBS)
libertynewsrecord.com - December 3 at 8:03 AM
News IconStock Concentration on Shares of Caladrius Biosciences Inc. (CLBS) - Yankee Analysts (NASDAQ:CLBS)
yankeeanalysts.com - December 2 at 4:41 PM
capitalcube.com logoETFs with exposure to Caladrius Biosciences, Inc. : December 2, 2016 (NASDAQ:CLBS)
www.capitalcube.com - December 2 at 4:41 PM
News IconInvestor Focus: Watching Shares of Caladrius Biosciences, Inc. (NASDAQ:CLBS) - OIB News (NASDAQ:CLBS)
oibnews.com - November 30 at 8:31 AM
News IconTrading Views: Checking the Numbers for Caladrius Biosciences Inc. (CLBS) - Yankee Analysts (NASDAQ:CLBS)
yankeeanalysts.com - November 30 at 8:31 AM
News IconCaladrius Biosciences, Inc. CLBS Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:CLBS)
www.bioportfolio.com - November 24 at 12:09 PM
News IconLevels in Review for Caladrius Biosciences, Inc. (NASDAQ:CLBS) - Wall Street Lion (NASDAQ:CLBS)
wslnews.com - November 23 at 9:06 PM
News IconLooking at the Gauges on Caladrius Biosciences Inc. (CLBS) - Yankee Analysts (NASDAQ:CLBS)
yankeeanalysts.com - November 23 at 9:06 PM

Social

What is Caladrius Biosciences' stock symbol?

Caladrius Biosciences trades on the NASDAQ under the ticker symbol "CLBS."

Where is Caladrius Biosciences' stock going? Where will Caladrius Biosciences' stock price be in 2017?

4 brokerages have issued 1 year price objectives for Caladrius Biosciences' stock. Their forecasts range from $1.25 to $6.50. On average, they anticipate Caladrius Biosciences' stock price to reach $3.88 in the next year.

When will Caladrius Biosciences announce their earnings?

Caladrius Biosciences is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.

Who owns Caladrius Biosciences stock?

Caladrius Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.00%). Company insiders that own Caladrius Biosciences stock include David J Mazzo, Eric Wei and Robert S Vaters.

Who bought Caladrius Biosciences stock? Who is buying Caladrius Biosciences stock?

Caladrius Biosciences' stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Caladrius Biosciences stock in the last two years include David J Mazzo and Robert S Vaters.

How do I buy Caladrius Biosciences stock?

Shares of Caladrius Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Caladrius Biosciences stock cost?

One share of Caladrius Biosciences stock can currently be purchased for approximately $5.23.

Caladrius Biosciences (NASDAQ:CLBS) Chart for Monday, February, 20, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Caladrius Biosciences (NASDAQ:CLBS)

Earnings History Chart

Earnings by Quarter for Caladrius Biosciences (NASDAQ:CLBS)

Dividend History Chart

Dividend Payments by Quarter for Caladrius Biosciences (NASDAQ:CLBS)

Last Updated on 2/20/2017 by MarketBeat.com Staff